Best Whole Genome Sequencing Providers in 2026

The consumer whole genome sequencing market in 2026 is smaller and more precarious than it was two years ago. Two significant providers have been through bankruptcy proceedings since 2025. One brand shut down entirely, leaving customers holding VCF files with nowhere to analyse them.

That context should shape how you choose. In this market, "will this company still exist when I need my data?" is not a paranoid question. It is a buying criterion.

What actually matters when choosing

Ignore the report counts in the marketing. Here is what determines whether you get value.

1. Coverage depth

Expressed as "30x" or "1x." It means how many times, on average, each position in your genome was read. More reads means more confidence in each call.

• 30x is the clinical-grade standard. This is what you want.
• 1x–2x ("low-pass") reads each position once or twice on average. Adequate for ancestry and matching. Not adequate for confident variant calling in a health context. Several products marketed as "whole genome sequencing" are low-pass, and the distinction is not always made loudly.

2. Raw file access — and whether it costs extra

This is the criterion people most often overlook and most often regret.

• FASTQ — the raw sequencing reads. Large, and the most flexible starting point.
• BAM — reads aligned to a reference genome.
• VCF — the list of variants where you differ from the reference.

If a provider does not give you these, you have not bought a genome. You have rented a subscription to their interpretation of one. And when that company folds — which, as recent history shows, happens — you are left with nothing.

3. Company survival

Newly relevant, and now unavoidable.

ProPhase Labs, the parent company of Nebula Genomics and DNA Complete, filed for Chapter 11 bankruptcy protection in September 2025 according to public SEC filings, and some customers experienced delayed kit shipments and support issues during that period. Nebula Genomics itself shut down on February 5, 2025, leaving a substantial number of customers with a whole genome VCF file and no platform on which to run reports.

Separately, 23andMe filed for bankruptcy in March 2025 and was subsequently sold, and continues to operate under new ownership.

The lesson is not "avoid all these companies." It is: download your raw files the moment they are available, and store them yourself. If you have your FASTQ and VCF on your own drive, a company's collapse is an inconvenience. If you do not, it is a total loss.

The 2026 providers

Dante Labs — best overall, with real caveats

Why it wins: Dante Labs offers 30x clinical-grade WGS at around EUR 399 standard, with full FASTQ/BAM/VCF included at no extra cost. Flash sales occur roughly three to four times a year — Black Friday, DNA Day, New Year, mid-summer — dropping the price to approximately EUR 169.

At standard pricing it is not the cheapest — Sequencing.com's $379 kit and DNA Complete's $195 1x option undercut it. But for 30x clinical-grade WGS with full raw data access included at no extra cost, Dante Labs flash sales remain the lowest price available to consumers.

To put that in perspective: during a flash sale you can obtain clinical-grade 30x whole genome sequencing for less than a basic AncestryDNA kit cost five years ago.

It is also a non-subscription model — you pay once and retain platform access, rather than paying monthly to look at your own data.

Sequencing.com — best at standard pricing, and fastest

Sequencing.com offers 30x WGS plus a microarray in its "Ultimate Genome" kit at $379, making it the cheapest at standard (non-sale) pricing, with an app marketplace of 30+ analysis tools, BAM/VCF data access included, and a 4–6 week turnaround per user reports.

The 30x-plus-microarray combination is genuinely clever. The array gives clean, well-validated genotype calls at common positions; the sequencing gives you everything else. And Sequencing.com accepts Nebula VCFs and runs them through its app marketplace — useful if you are one of the people stranded by that shutdown.

If you do not want to wait for a Dante Labs flash sale and you value predictable turnaround, this is the pick.

Nucleus Genomics

Nucleus Genomics ($399 plus $39/year) and Dante Labs (~$430) are described as the leading active WGS providers in 2026. Nucleus is the newest serious entrant and worth watching. Note the annual fee — factor it into the true cost of ownership over several years.

DNA Complete (formerly Nebula Genomics)

DNA Complete offers tiered pricing: 1x screening at $195, 30x clinical at $495, and up to 100x ultra-deep, and formerly operated under the Nebula Genomics brand with its privacy-first design.

Two cautions. First, the parent company's Chapter 11 filing. As of early 2026 DNA Complete appears to be operating and fulfilling orders based on recent user reports, but prospective buyers should be aware of the financial uncertainty and consider paying with a credit card offering purchase protection. Second, FASTQ access is a $99 add-on on top of the $495 30x price, which materially changes the value calculation.

The 1x option at $195 deserves a specific warning: it is low-pass. It is fine for ancestry. It is not a substitute for 30x if your interest is health.

What about upload-and-analyse services?

Companies like SelfDecode, Genomelink and Genomisaur do not sequence anything. They take a file you already have and run analyses on it.

These can be genuinely good value — if you already have data. Sequencing.com accepts Nebula VCFs; SelfDecode accepts SNP-array uploads but not always raw VCFs; Genomisaur offers polygenic risk score reports on WGS VCFs.

But be clear about what you are buying: interpretation, not data. If you do not already have a genome, an upload service cannot give you one. And no interpretation service can invent information the underlying test never captured — an analysis of a 700,000-marker array is still an analysis of 700,000 markers, however sophisticated the algorithm layered on top.

How to choose, decisively

The bottom line

Whole genome sequencing in 2026 is cheaper and better than it has ever been, delivered by an industry that is visibly consolidating and financially fragile.

Buy 30x, not low-pass. Insist on raw files included in the price. Download them immediately. And weigh turnaround honestly against price — Dante Labs is the best value in the market and also the slowest, and both of those things are true at once.